Anixa Biosciences, ordinary share
ANIX, US03528H1095
CBONDSウォッチリストで投資を発見、保存、追跡
Cbondsウォッチリストを使用すれば、常に投資状況を最新の状態に保ち、意識的な意思決定が可能です!
Cbondsウォッチリストを使用すれば、常に投資状況を最新の状態に保ち、意識的な意思決定が可能です!
最も包括的なデータベースを探索
1 000 000
債券
100 000
株
175 910
ETF&投資信託
100 000
インデックス
最も効率的な方法でポートフォリオを追跡
|
By using the body's immune system, Anixa Biosciences, Inc. (former ITUS Corporation) is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those
...
By using the body's immune system, Anixa Biosciences, Inc. (former ITUS Corporation) is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.
|
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |